View Older Stories View More Recent Stories

Jun 27, 2023 04:05PM Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
May 11, 2023 04:05PM Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
Mar 23, 2023 04:50PM Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
Mar 23, 2023 04:50PM Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
Mar 8, 2023 07:00AM Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
Mar 8, 2023 07:00AM Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
Feb 10, 2023 04:05PM Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
Feb 10, 2023 04:05PM Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
Dec 15, 2022 07:00AM Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
Dec 15, 2022 07:00AM Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
Nov 9, 2022 04:05PM Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
Nov 9, 2022 04:05PM Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
Nov 1, 2022 07:00AM Rezolute to Present at the Jefferies London Healthcare Conference
Nov 1, 2022 07:00AM Rezolute to Present at the Jefferies London Healthcare Conference
Oct 20, 2022 07:00AM Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
Oct 20, 2022 07:00AM Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
Sep 15, 2022 04:05PM Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress
Sep 15, 2022 04:05PM Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress
Sep 7, 2022 07:00AM Rezolute Announces Presentation at the 60th Annual ESPE Meeting
Sep 7, 2022 07:00AM Rezolute Announces Presentation at the 60th Annual ESPE Meeting
Jun 1, 2022 07:04AM Rezolute Inc. (RZLT) Appoints Brian Roberts as Chief Medical Officer
Jun 1, 2022 07:00AM Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
Jun 1, 2022 07:00AM Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
May 12, 2022 04:05PM Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
May 12, 2022 04:05PM Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
May 4, 2022 04:01PM Rezolute to Host Corporate Update Call on May 4, 2022
May 4, 2022 04:01PM Rezolute to Host Corporate Update Call on May 4, 2022
May 4, 2022 09:33AM Rezolute, Inc. Announces Closing of Registered Direct Offering
May 4, 2022 09:33AM Rezolute, Inc. Announces Closing of Registered Direct Offering
May 2, 2022 05:56AM Rezolute Inc. (RZLT) Reports Positive Data from Phase 2b (RIZE) Study of RZ358
May 2, 2022 05:55AM Rezolute Inc. (RZLT) Prices 18M Share Offering at $3.80/sh
May 1, 2022 11:25PM Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
May 1, 2022 11:25PM Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
May 1, 2022 02:00PM Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
May 1, 2022 02:00PM Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
Apr 26, 2022 04:05PM RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022
Apr 26, 2022 04:05PM RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022
Mar 29, 2022 07:00AM Rezolute Joins the Rare Disease Company Coalition
Mar 29, 2022 07:00AM Rezolute Joins the Rare Disease Company Coalition
Mar 23, 2022 07:00AM Rezolute Inc. (RZLT) Reports Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
Mar 23, 2022 07:00AM Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
Mar 23, 2022 07:00AM Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
Feb 22, 2022 07:05AM Rezolute Inc. (RZLT) Reports Positive Study Results for RZ402
Feb 22, 2022 07:00AM Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME
Feb 22, 2022 07:00AM Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME
Feb 9, 2022 04:05PM Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress
Feb 9, 2022 04:05PM Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress
Nov 12, 2021 04:05PM Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
Nov 12, 2021 04:05PM Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
Oct 13, 2021 08:12AM Rezolute Inc. (RZLT) Prices 6.03M Share Offering at $6.50/sh and Concurrent Registered Offering of 769k Shares at $6.50/sh
View More Recent Stories View Older Stories